9877 (9877) Fair Value & Analysis

Healthcare · Market cap HK$3.0B

9 9877 9877 · HK

PriceHK$7.12

Fair ValueHK$1.60

Upside-77.5%

Quality44/100

Watch 9877 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$1.06 – HK$2.00

Fair value as of: Jul 3, 2026

From 1 valuation models · updated today

Share price −13.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$6.77 – HK$11.98 · fair‑value band HK$1.06 – HK$2.00 · the HK$7.12 price screens above the HK$1.60 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

9877 (9877) currently trades at HK$7.12, while our model-based Fair Value estimate is HK$1.60 — implying the stock looks roughly 77.5% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at HK$90.6M. It earns a return on equity of -32.3%. The balance sheet holds a net cash position of HK$460M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$90.6M

Net margin -299%

Return on equity -32.3%

Free cash flow −HK$80.1M FY2025

Operating margin -121%

EPS (TTM) HK$-0.4100

More key figures

Net cash HK$460M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

9877 reported revenue of HK$88.2M in FY2025 versus HK$0 in FY2021. Reported net income was −HK$264M in FY2025.

Revenue

FY21 HK$0

FY22 HK$0

FY23 HK$0

FY24 HK$0

FY25 HK$88.2M

Net income

FY21 −HK$501M

FY22 −HK$439M

FY23 −HK$372M

FY24 −HK$178K

FY25 −HK$264M

Is 9877 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.21	R$43.74	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 9877 (9877) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$1.60 versus a price of HK$7.12 — about −78% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 9877?

Our model-based fair value for 9877 is HK$1.60 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$7.12.

What is the quality score of 9877?

9877 has a Quality Score of 44/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 9877 (9877)?

9877 reported trailing-twelve-month revenue of about HK$90.6M (latest available figure, as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.